The decline in Cue Biopharma's stock price is directly tied to the market's reaction to its Q1 adjusted EPS results. Typically, earnings reports can significantly influence investor sentiment and stock prices, especially if the results are below market expectations. The specific details of the EPS results are not provided, but the negative stock price movement suggests that the results may have not met investor expectations.